Literature DB >> 26984268

CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Anke Steinmetz1, François Vallée1, Christian Beil2, Christian Lange2, Nicolas Baurin1, Jochen Beninga2, Cécile Capdevila3, Carsten Corvey2, Alain Dupuy1, Paul Ferrari3, Alexey Rak1, Peter Wonerow2, Jochen Kruip2, Vincent Mikol1, Ercole Rao2.   

Abstract

Bispecific immunoglobulins (Igs) typically contain at least two distinct variable domains (Fv) that bind to two different target proteins. They are conceived to facilitate clinical development of biotherapeutic agents for diseases where improved clinical outcome is obtained or expected by combination therapy compared to treatment by single agents. Almost all existing formats are linear in their concept and differ widely in drug-like and manufacture-related properties. To overcome their major limitations, we designed cross-over dual variable Ig-like proteins (CODV-Ig). Their design is akin to the design of circularly closed repeat architectures. Indeed, initial results showed that the traditional approach of utilizing (G4S)x linkers for biotherapeutics design does not identify functional CODV-Igs. Therefore, we applied an unprecedented molecular modeling strategy for linker design that consistently results in CODV-Igs with excellent biochemical and biophysical properties. CODV architecture results in a circular self-contained structure functioning as a self-supporting truss that maintains the parental antibody affinities for both antigens without positional effects. The format is universally suitable for therapeutic applications targeting both circulating and membrane-localized proteins. Due to the full functionality of the Fc domains, serum half-life extension as well as antibody- or complement-dependent cytotoxicity may support biological efficiency of CODV-Igs. We show that judicious choice in combination of epitopes and paratope orientations of bispecific biotherapeutics is anticipated to be critical for clinical outcome. Uniting the major advantages of alternative bispecific biotherapeutics, CODV-Igs are applicable in a wide range of disease areas for fast-track multi-parametric drug optimization.

Entities:  

Keywords:  ADCC; CDC; CODV-Fab crystal structure; T-cell engager; bispecific biotherapeutics; bivalent immunoglobulin; protein design; protein-protein docking; tetravalent format

Mesh:

Substances:

Year:  2016        PMID: 26984268      PMCID: PMC4968095          DOI: 10.1080/19420862.2016.1162932

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  94 in total

1.  Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.

Authors:  P Sondermann; J Kaiser; U Jacob
Journal:  J Mol Biol       Date:  2001-06-08       Impact factor: 5.469

2.  A hierarchical approach to all-atom protein loop prediction.

Authors:  Matthew P Jacobson; David L Pincus; Chaya S Rapp; Tyler J F Day; Barry Honig; David E Shaw; Richard A Friesner
Journal:  Proteins       Date:  2004-05-01

Review 3.  Designing proteins from simple motifs: opportunities in Top-Down Symmetric Deconstruction.

Authors:  Michael Blaber; Jihun Lee
Journal:  Curr Opin Struct Biol       Date:  2012-06-20       Impact factor: 6.809

4.  Probing the alpha-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis.

Authors:  Zuojun Guo; Udayan Mohanty; Justin Noehre; Tomi K Sawyer; Woody Sherman; Goran Krilov
Journal:  Chem Biol Drug Des       Date:  2010-04       Impact factor: 2.817

5.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

6.  Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.

Authors:  Enrico L Digiammarino; John E Harlan; Karl A Walter; Uri S Ladror; Rohinton P Edalji; Charles W Hutchins; Marc R Lake; Amy J Greischar; Junjian Liu; Tariq Ghayur; Clarissa G Jakob
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

7.  A systematic comparison of free and bound antibodies reveals binding-related conformational changes.

Authors:  Inbal Sela-Culang; Shahar Alon; Yanay Ofran
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

8.  A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

Authors:  Gurunadh R Chichili; Ling Huang; Hua Li; Steve Burke; Leilei He; Qin Tang; Linda Jin; Sergey Gorlatov; Valentina Ciccarone; Francine Chen; Scott Koenig; Michele Shannon; Ralph Alderson; Paul A Moore; Syd Johnson; Ezio Bonvini
Journal:  Sci Transl Med       Date:  2015-05-27       Impact factor: 17.956

9.  Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup.

Authors:  E H Sasso; G J Silverman; M Mannik
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

10.  Improving target cell specificity using a novel monovalent bispecific IgG design.

Authors:  Yariv Mazor; Vaheh Oganesyan; Chunning Yang; Anna Hansen; Jihong Wang; Hongji Liu; Kris Sachsenmeier; Marcia Carlson; Dhanesh V Gadre; Martin Jack Borrok; Xiang-Qing Yu; William Dall'Acqua; Herren Wu; Partha Sarathi Chowdhury
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more
  24 in total

1.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors:  Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal:  Science       Date:  2017-09-20       Impact factor: 47.728

2.  Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.

Authors:  Lan Wu; Edward Seung; Ling Xu; Ercole Rao; Dana M Lord; Ronnie R Wei; Virna Cortez-Retamozo; Beatriz Ospina; Valeriya Posternak; Gregory Ulinski; Peter Piepenhagen; Elisa Francesconi; Nizar El-Murr; Christian Beil; Patrick Kirby; Aiqun Li; Jennifer Fretland; Rita Vicente; Gejing Deng; Tarik Dabdoubi; Beatrice Cameron; Thomas Bertrand; Paul Ferrari; Stéphanie Pouzieux; Cendrine Lemoine; Catherine Prades; Anna Park; Huawei Qiu; Zhili Song; Bailin Zhang; Fangxian Sun; Marielle Chiron; Srinivas Rao; Katarina Radošević; Zhi-Yong Yang; Gary J Nabel
Journal:  Nat Cancer       Date:  2019-11-18

3.  A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.

Authors:  Edward Seung; Zhen Xing; Lan Wu; Ercole Rao; Virna Cortez-Retamozo; Beatriz Ospina; Liqing Chen; Christian Beil; Zhili Song; Bailin Zhang; Mikhail Levit; Gejing Deng; Andrew Hebert; Patrick Kirby; Aiqun Li; Emma-Jane Poulton; Rita Vicente; Audrey Garrigou; Peter Piepenhagen; Greg Ulinski; Michele Sanicola-Nadel; Dinesh S Bangari; Huawei Qiu; Lily Pao; Dmitri Wiederschain; Ronnie Wei; Zhi-Yong Yang; Gary J Nabel
Journal:  Nature       Date:  2022-02-23       Impact factor: 69.504

Review 4.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

Review 5.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

6.  Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments.

Authors:  Timothy J Egan; Dania Diem; Richard Weldon; Tessa Neumann; Sebastian Meyer; David M Urech
Journal:  MAbs       Date:  2016-10-27       Impact factor: 5.857

Review 7.  Engineering multi-specific antibodies against HIV-1.

Authors:  Neal N Padte; Jian Yu; Yaoxing Huang; David D Ho
Journal:  Retrovirology       Date:  2018-08-29       Impact factor: 4.602

Review 8.  The use of CrossMAb technology for the generation of bi- and multispecific antibodies.

Authors:  Christian Klein; Wolfgang Schaefer; Jörg T Regula
Journal:  MAbs       Date:  2016-06-10       Impact factor: 5.857

9.  Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.

Authors:  Guillaume Desoubeaux; Janice M Reichert; Matthew Sleeman; Karen L Reckamp; Bernhard Ryffel; Jörg P Adamczewski; Theresa D Sweeney; Rita Vanbever; Patrice Diot; Caroline A Owen; Clive Page; Stéphanie Lerondel; Alain Le Pape; Nathalie Heuze-Vourc'h
Journal:  MAbs       Date:  2016-06-06       Impact factor: 5.857

10.  Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody.

Authors:  Dana M Lord; Julie J Bird; Denise M Honey; Annie Best; Anna Park; Ronnie R Wei; Huawei Qiu
Journal:  MAbs       Date:  2018-02-01       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.